Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ImmuCell Corporation (ICCC) stocks in Canada

Learn how to easily invest in ImmuCell Corporation stocks.

ImmuCell Corporation is a biotechnology business based in the US. ImmuCell Corporation stocks (ICCC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $9.63 – an increase of 1.59% over the previous week. ImmuCell Corporation employs 59 staff and has a trailing 12-month revenue of around $17.5 million.

How to buy shares in ImmuCell Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ICCC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ImmuCell Corporation stock price (NASDAQ:ICCC)

Use our graph to track the performance of ICCC stocks over time.

ImmuCell Corporation shares at a glance

Information last updated 2022-01-18.
Latest market close$8.95
52-week range$6.70 - $13.20
50-day moving average $8.79
200-day moving average $9.35
Wall St. target price$14.00
PE ratio 1761.32
Dividend yield N/A (0%)
Earnings per share (TTM) $0.01

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy ImmuCell Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

ImmuCell Corporation price performance over time

Historical closes compared with the close of $8.95 from 2022-01-21

1 week (2022-01-14) 1.59%
1 month (2021-12-23) 7.70%
3 months (2021-10-22) 0.45%
6 months (2021-07-23) -12.60%
1 year (2021-01-22) 23.45%
2 years (2020-01-24) 65.13%
3 years (2019-01-24) 16.99%
5 years (2017-01-24) 53.28%

Is ImmuCell Corporation under- or over-valued?

Valuing ImmuCell Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ImmuCell Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ImmuCell Corporation's P/E ratio

ImmuCell Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1761x. In other words, ImmuCell Corporation shares trade at around 1761x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

ImmuCell Corporation's EBITDA

ImmuCell Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2 million.

The EBITDA is a measure of a ImmuCell Corporation's overall financial performance and is widely used to measure a its profitability.

ImmuCell Corporation financials

Revenue TTM $17.5 million
Gross profit TTM $6.9 million
Return on assets TTM -0.78%
Return on equity TTM 0.12%
Profit margin 0.21%
Book value $4.19
Market capitalisation $68.2 million

TTM: trailing 12 months

ImmuCell Corporation share dividends

We're not expecting ImmuCell Corporation to pay a dividend over the next 12 months.

Have ImmuCell Corporation's shares ever split?

ImmuCell Corporation's shares were split on a 1:100 basis on 24 July 1990. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ImmuCell Corporation shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for ImmuCell Corporation shares which in turn could have impacted ImmuCell Corporation's share price.

ImmuCell Corporation share price volatility

Over the last 12 months, ImmuCell Corporation's shares have ranged in value from as little as $6.7001 up to $13.2. A popular way to gauge a stock's volatility is its "beta".

ICCC.US volatility(beta: 0.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmuCell Corporation's is 0.7086. This would suggest that ImmuCell Corporation's shares are less volatile than average (for this exchange).

ImmuCell Corporation overview

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Stocks similar to ImmuCell Corporation

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site